Yes, we are going to see about Kiran Mazumdar-Shaw who is a Biocon Chairperson Accidental Entrepreneur Story. In this blog, we are going to see about her journey, successes as well as failures he faced in his journey.
Table of Contents
Introduction:
The journey begins with Padma Shri Kiran Mazumdar-Shaw who created a revolution in the field of the pharmaceutical industry. It started in 1978 were Kiran Mazumdar-Shaw was applying for a job and he fails to get it who holds a degree from Australia, at that time Biocon Chairperson Accidental Entrepreneur Story she faced many difficulties while getting a job but accidentally he meets an Irish biotech entrepreneur who told her that he wants to start a company in India.
I also heard a lot about you from Australia if you become a partner I can start the company in India where she told me that I am not the right partner because I don’t have the capital as well as any business experience. Biocon Chairperson Accidental Entrepreneur Story I am just in search of a job where he said that he has the skill of entrepreneurship you can take a try then she taught me that this is an opportunity and she has to use that in a great manner.
Biocon Company Overview:
Biocon is a global biopharmaceutical company changing lives in over 120 countries by finding new and Biocon Chairperson Accidental Entrepreneur Story affordable ways to treat diabetes, cancer, etc. The company was started in 1978 with the mission to make a medicine that can be used by a minimum of 100 crore people their Biocon Chairperson Accidental Entrepreneur Story main priorities are PATIENT CENTRICITY, FOCUS ON SCIENCE, ACCESS TO ALL, QUALITY FIRST, and PEOPLE POWER.
| Company name | BIOCON |
| Founders | Kiran Mazumdar-Shaw |
| Started at | 1978 |
| Competitors | EMS Pharma, Cipla, Sun Pharma, and Idorsia |
| Website | https://www.biocon.com/ |
| country | India |
| City | Bengaluru |
| Revenue | FY22 Revenue at Rs 8,397 Cr |
| Industry | Pharmaceutical |
| Headquarters | Bengaluru |
Biocon History:
Biocon was founded in 1978 with Rs.10,000 as the initial capital and the age of Kiran Mazumdar-Shaw was just 25 years. Biocon Chairperson Accidental Entrepreneur Story and 1979 – Becomes the first Indian company to manufacture and export enzymes to the US and Europe. 1989 – Unilever acquires Biocon Biochemicals Ltd.
She started the company in an unknown territory with high financial risk because at that time the word biochemical was not so famous, Biocon Chairperson Accidental Entrepreneur Story so the banks are not ready to provide loans to the company also because she has no consolidation to keep.
Biocon Struggles:
- Banks are not ready to provide loans because she does not have any collateral to keep.
- While taking interviews the interviewers are not ready to work under a woman because she was the boss and also, Biocon Chairperson Accidental Entrepreneur Story and they are afraid for their job security.
- She was suffering from both capital and manpower, but times changed.
Biocon Success:
There is the fact that after the dark bright appears, here are a few achievements she earned.
- India’s Top 5 powerful women
- World’s Top 25 powerful women
- Medicine – 100 crore people
- Market Cap – 31000 crore
- Turnover – 6000 crore
- Employees – 12000
- Research Scientists
- In 1978 – Fastest Billionaire
Biocon Awards:
| NO | AWARDS | YEAR |
| 1. | PADMA SHRI | 1989 |
| 2. | PADMA BHUSHAN | 2005 |
| 3. | BUSINESSWOMAN OF THE YEAR BY ECONOMIC TIMES | 2004 |
| 4. | DYNAMIC ENTREPRENEUR | 2009 |
| 5. | BUSINESSPERSON OF THE YEAR | 2006 |
| 6. | THE CORPORATE LEADERSHIP | 2005 |
| 7. | KARNATAKA RAJYOTSAVA | 2002 |
| 8. | OTHMER GOLD MEDAL | 2014 |
| 9. | THE NIKKEI ASIA PRIZE | 2009 |
| 10. | VEUVE CLIXQUOT | 2007 |
| 11. | TECHNOLOGY PIONEER | 2002 |
| 12. | AUSTRALIA’S HIGHEST CIVILIAN | 2020 |
Biocon On Nowadays:
The company nowadays is considered as a top 3 organization in the field of the pharmaceutical industry with a market capitalization of 31000 crores.
Biocon’s core philosophy is based on research lead as well as creating a vast opportunity for the scientists.
Biocon Board of Directors:
The team members of Biocon are listed below:
| NO. | DESIGNATION | NAME |
| 1. | Executive Chairperson | KIRAN MAZUMDAR SHAW |
| 2. | CEO and Managing Director | SIDDHART MITTAL |
| 3. | Non-Executive Director | RAVI MAZUMDAR |
| 4. | Independent and Non-Executive Director | VIJAY KUCHROO |
| 5. | Independent and Non-Executive Director | BOBBY KANUBHAI PARIKH |
| 6. | Independent and Non-Executive Director | M.DAMODARAN |
| 7. | Non-Executive Director | ERIC MAZUMDAR |
| 8. | Independent and Non-Executive Director | NAINA LAL KIDWAI |
Biocon Management Team:
| NO. | DESIGNATION | NAME |
| 1. | Executive Chairperson Biocon Limited and Biocon Biologics Limited | KIRAN MAZUMDAR SHAW |
| 2. | Managing Director Biocon Biologics Limited | DR. ARUN CHANDAVARKAR |
| 3. | CEO & Managing Director Biocon Limited | SIDDHART MITTAL |
| 4. | Deputy Chief Executive Officer Biocon Biologics Limited | SHREEHAS P TAMBE |
| 5. | CEO & Managing Director Syngene International | JONATHAN HUNT |
Biocon Employees:
The company Biocon created a number of opportunities for researchers who are interested in the field of pharmaceuticals. The company Biocon Chairperson Accidental Entrepreneur Story has provided employability to12000 employees among them there are 6000 scientists were employed.
Biocon Products:
The company Biocon created a number of products that fills the global medical need, their products as classified into different categories,
- Generics
- Biosimilars
- Branded Formulation
- Novel biologics
Biocon Generic Formulations:
| Sl. No | Molecule Name | Status |
| 1 | Rosuvastatin | Commercial (United States, Europe) |
| 2 | Simvastatin | Commercial (United States) |
| 3 | Atorvastatin | Commercial (United States) |
| 4 | Fingolimod | Approved (United States, Europe) |
| 5 | Dapagliflozin | Tentative Approval (United States) |
| 6 | Pemetrexed | Tentative Approval (United States) |
| 7 | Tacrolimus | Commercial (United States) |
| 8 | Everolimus (RLD Affinitor) | Commercial (United States), Approved (Europe) |
| 9 | Pravastatin | Commercial (United States) |
| 10 | Labetalol | Commercial (United States) |
| 11 | Esomeprazole | Commercial (United States) |
| 12 | Posaconazole | Commercial (United States) |
Biocon API:
| Sl. No | Cardiology (Molecule Name) |
| 1 | Simvastatin |
| 2 | Pravastatin |
| 3 | Atorvastatin |
| 4 | Rosuvastatin |
| 5 | Fluvastatin |
| 6 | Dabigatran |
| 7 | Sacubitril/Valsartan |
| 8 | Apixaban |
| 9 | Rivaroxaban |
| Sl. No | Anti-Diabetics (Molecule Name) |
| 1 | Vildagliptin |
| 2 | Linagliptin |
| 3 | Sitagliptin (various salts) |
| 4 | Dapagliflozin (different solvate forms) |
| 5 | Empagliflozin |
| 6 | Repaglinide |
| 7 | Liraglutide |
| 8 | Semaglutide |
| Sl. No | Immunosuppressants (Molecule Name) |
| 1 | Tacrolimus |
| 2 | Sirolimus |
| 3 | Everolimus |
| 4 | Pimecrolimus |
| 5 | Mycophenolate Mofetil (MMF) |
| 6 | Mycophenolate Sodium (MPS) |
| Sl. No | Multiple Sclerosis (Molecule Name) |
| 1 | Glatiramer Acetate |
| 2 | Fingolimod |
| 3 | Teriflunomide |
| Sl. No | Anti-Cancer/Oncology (Molecule Name) |
| 1 | Dasatinib |
| 2 | Lenalidomide |
| 3 | Pazopanib |
| 4 | Erdafitinib |
| Sl. No | Other Key Products (Molecule Name) |
| 1 | Orlistat |
| 2 | Mirabegron |
| 3 | Posaconazole |
| 4 | Micafungin |
| 5 | Anidulafungin |
| 6 | Brinzolamide |
Biocon Achievements and Milestones:
As a company, it is easy to keep a milestone, but it is hard to achieve it, Biocon has achieved a number of milestones in the recent 44 years.
| NO. | ACHIEVEMENTS | YEAR |
| 1. | Biocon’s Founding Day | 1978 |
| 2. | First export of Papain, a plant enzyme derived from Papaya | 1979 |
| 3. | Biocon’s groundbreaking of its heritage campus on 20th KM, Hosur Road, Bangalore | 1980 |
| 4. | Biocon starts construction at its own site | 1981 |
| 5. | Biocon’s Bangalore campus is inaugurated | 1983 |
| 6. | R&D division established to develop Solid State Enzyme Fermentation Technology | 1984 |
| 7. | Unilever Acquires Biocon’s Irish Parent | 1989 |
| 8. | Scaling up indigenous fermentation technology | 1990 |
| 9. | First Life Sciences Company from India to get ISO 9001 Certification | 1993 |
| 10. | Biocon establishes Syngene International Pvt. Ltd | 1994 |
| 11. | Biocon Quest India Ltd (BQIL) is established | 1995 |
| 12. | Biocon becomes an independent entity | 1998 |
| 13. | Nobel Laureate Prof. James D Watson visits Biocon | 1999 |
| 14. | Clinigene – India’s first Clinical Research Services Organization | 2000 |
| 15. | Biocon’s proprietary bioreactor, PlaFractor, is commissioned | 2000 |
| 16. | First fully automated submerged fermentation plant commissioned | 2000 |
| 17. | First company globally to be approved by U.S. FDA to sell Lovastatin API | 2001 |
| 18. | Patent granted for proprietary PlaFractor technology | 2001 |
| 19. | Biocon Biopharmaceuticals established as a JV with CIMAB, Cuba | 2002 |
| 20. | World’s first Pichia-based rh-Insulin developed and commercialized in India | 2004 |
| 21. | Biocon makes a resounding debut on the Indian stock market | 2004 |
| 22. | Biocon Park, India’s first private Biotechnology SEZ, inaugurated | 2006 |
| 23. | First company in India to launch a novel biologic, Nimotuzumab | 2006 |
| 24. | India’s largest multi-product Biologics facility inaugurated | 2006 |
| 25. | Biocon divests enzymes business | 2007 |
| 26. | Biocon acquires stake in AISCorp. GmbH, a German pharmaceutical company | 2008 |
| 27. | Biocon, Mylan enter strategic global partnership for development of biosimilars | 2009 |
| 28. | Biocon launches Basalog® (Insulin Glargine) in India | 2009 |
| 29. | Biocon Bristol-Myers Squibb Research Centre (BBRC) inaugurated | 2009 |
| 30. | Biocon and Pfizer enter into a strategic global agreement | 2010 |
| 31. | Biocon starts work on the largest integrated insulins facility in Asia | 2011 |
| 32. | Biocon launches INSUPen® for patients in India | 2011 |
| 33. | Biocon Research Centre Inaugurated | 2012 |
| 34. | The world’s first anti-CD6 monoclonal antibody Itolizumab commercialized in India | 2013 |
| 35. | Biocon House inaugurated | 2013 |
| 36. | Biocon establishes Biocon Academy under its CSR agenda | 2013 |
| 37. | Biocon introduces the world’s first biosimilar Trastuzumab, CANMAb™, in India | 2014 |
| 38. | Syngene debuts on the Indian stock market | 2015 |
| 39. | Biocon’s new insulin devices facility inaugurated in Bangalore | 2015 |
| 40. | Biocon Gets its First Generic Formulation Approval in the EU | 2016 |
| 41. | First biosimilar from India to be approved in Japan | 2016 |
| 42. | First company from India to get U.S. FDA approval for a biosimilar | 2017 |
| 43. | Biocon’s first overseas facility in Malaysia starts operations | 2017 |
| 44. | Biocon out licenses Itolizumab to Equillium for U.S., Canada | 2017 |
| 45. | Biocon launches its biosimilar Bevacizumab in India | 2017 |
| 46. | First company from India to have biosimilar commercialized in the U.S. | 2018 |
| 47. | Semglee is the first biosimilar from Biocon & Mylan’s joint insulins portfolio to be approved in Europe | 2018 |
| 48. | Biocon, Sandoz enter global partnership for next-gen biosimilars | 2018 |
| 49. | Two biosimilars get marketing authorization in the EU | 2018 |
| 50. | Biosimilars business consolidated under the independent entity Biocon Biologics | 2019 |
| 51. | Ogivri, biosimilar Trastuzumab, commercialized in the U.S | 2019 |
| 52. | Bicara Therapeutics incorporated to advance novel immuno-oncology assets | 2019 |
| 53. | True North makes a primary equity investment in Biocon Biologics | 2020 |
| 54. | Itolizumab Gets DCGI Nod for Restricted Emergency Use in Moderate to Severe COVID-19 Patients | 2020 |
| 55. | Tata Capital picks up a minority stake in Biocon Biologics | 2020 |
| 56. | Semglee™ (insulin glargine injection) Launched in the U.S. | 2020 |
| 57. | Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs | 2020 |
| 58. | Biocon Biologics Receives USD 75 Million Capital Injection from ADQ | 2021 |
| 59. | Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-19 | 2021 |
| 60. | Semglee® Receives Historic U.S. Approval for First Interchangeable Biosimilar | 2021 |
| 61. | Biocon Biologics and Serum Institute Life Sciences Enter Strategic Alliance | 2021 |
| 62. | Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index | 2021 |
| 63. | Biocon Biologics Inks Deal to Acquire Viatris’ Global Biosimilars Business for up to USD 3.335 billion | 2022 |
FAQs about Biocon Chairperson Accidental Entrepreneur Story:
How Kiran Mazumdar-Shaw started her business?
She started Biocon India in 1978 in the garage of her rented house in Bengaluru with a seed capital of Rs. 10,000. Biocon Chairperson Accidental Entrepreneur Story and Although it was a joint venture, Indian laws restricted foreign ownership to only 30% of the company, which meant that 70% of the company belonged to Kiran Mazumdar Shaw.
What are the challenges faced by Kiran Mazumdar-Shaw?
Her Struggles. Biocon Chairperson Accidental Entrepreneur Story “I faced a number of challenges whilst I built Biocon. Initially, Biocon Chairperson Accidental Entrepreneur Story I had credibility challenges where I couldn’t get banks to fund me; I couldn’t recruit people to work for a woman boss. Even in the businesses where I had to procure raw materials, they didn’t want to deal with women.”
Who was the chair person of Biocon?
Executive Chairperson – Biocon Limited and Biocon Biologics Limited. Kiran Mazumdar-Shaw is a first-generation entrepreneur Biocon Chairperson Accidental Entrepreneur Story and global business leader with over 4 decades of experience in biotechnology. Fueled by her passion, she started her biotech journey in 1978 from her garage in India.
Who are real leaders according to Kiran Mazumdar-Shaw?
According to Kiran Mazumdar-Shaw, true leaders are visionaries with a sense of purpose, who persevere and have a passion for change. Biocon Chairperson Accidental Entrepreneur Story They know that leadership is not about control but being able to inspire people with values and vision. Real leaders are those who spot opportunities where others see challenges.
How much is Kiran Mazumdar-Shaw worth?
Kiran Mazumdar-Shaw’s worth is 250 crores USD.
What happened when Kiran returned to India after completing her education in Australia?
Upon graduating, she held a string of jobs including that of a trainee brewer at Carlton and United Breweries as well as a trainer master Biocon Chairperson Accidental Entrepreneur Story at Barret Brothers and Burston in Australia. Upon enhancing her skills, she moved back to India wherein she worked as a trainee consultant at Jupiter Breweries in Calcutta.
How old is Kiran Mazumdar-Shaw?
Kiran Mazumdar-Shaw age is 69 years.
What is Biocon known for?
World’s first Pichia-based RH-Insulin developed and commercialized in India. Biocon is the first company in the world to commercialize Biocon Chairperson Accidental Entrepreneur Story recombinant human insulin (RH-insulin), Insugen®, using a novel Pichia pastoris yeast expression system. Today, Biocon’s RH-insulin is approved in over 40 countries.
What is the tagline for Biocon?
Biocon – India’s largest biopharmaceutical company. Hope. saves lives.
Why do you want to join Biocon?
Working with one of the world’s most advanced biopharmaceutical companies brings with it a tremendous Biocon Chairperson Accidental Entrepreneur Story opportunity to create a lasting impact on global health. Our strategy is to provide affordable access to a specialty portfolio of medicines for global patient populations.
Conclusion:
Biocon Chairperson Accidental Entrepreneur Story is working on the vision to provide medicines to people at a cost-effective price because they know how people suffer from chronic or other diseases and because of the high cost of the medicines many peoples are not getting treated.
